Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 8, Issue 7, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofab353
Keywords
antibody; COVID; 19 vaccine; hematological malignancy; SARS; CoV; 2
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K23AI154546]
Ask authors/readers for more resources
It was found that about half of patients with hematological malignancies did not produce sufficient immune response after receiving two doses of vaccine, with B-cell chronic lymphocytic leukemia patients at a higher risk. Therefore, these patients need to continue taking protective measures. More research is needed to understand revaccination, boosters, and immune protection correlates.
We measured severe acute respiratory syndrome coronavirus 2 immunoglobulin G responses in 67 patients with hematological malignancies after 2 messenger RNA vaccine doses. Forty-six percent were nonresponders; patients with B-cell chronic lymphocytic leukemia were at highest risk (77% nonresponders). Patients with hematological malignancies should continue wearing masks and socially distancing. Studies of revaccination, boosters, and humoral immune correlates of protection are needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
